文献速递肝肾功能剂量调整治疗药物监测与药物基因组学药物不良反应与药物警戒

普拉佐米星:新一代氨基糖苷类抗菌药

Plazomicin: A Next-Generation Aminoglycoside.
PubMed 文献 · Pharmacotherapy · 2019-01-08

普拉佐米星是一种新型氨基糖苷类抗菌药,通过与细菌30S核糖体亚基结合抑制蛋白质合成。III期试验显示其治疗cUTI不劣于美罗培南,对碳青霉烯耐药肠杆菌科感染有效且死亡率低于黏菌素。适用于替代治疗选择有限的成人cUTI,需根据肾功能调整剂量并开展治疗药物监测。

要点

  • 普拉佐米星对产ESBL及碳青霉烯耐药肠杆菌科等革兰阴性菌有广谱活性
  • III期试验中cUTI治愈率不劣于美罗培南,对CRE感染死亡率低于黏菌素
  • 适用于替代选择有限的成人cUTI,15 mg/kg IV q24h用4-7天,中重度肾损需减量并TDM

核心结论

  • 普拉佐米星为替代治疗选择有限的成人cUTI提供了新选择,尤其针对多重耐药革兰阴性杆菌感染。
  • 对碳青霉烯耐药肠杆菌科感染,普拉佐米星的全因死亡或显著疾病相关并发症率低于黏菌素。

研究设计与样本

  • 大型III期临床试验比较普拉佐米星与美罗培南治疗cUTI,共同主要终点为第5天和治愈访视时的微生物学改良意向治疗复合治愈率。
  • 小型III期临床试验评估普拉佐米星治疗碳青霉烯耐药肠杆菌科感染的效果。

主要发现

  • 第5天复合治愈率:普拉佐米星88%(168/191)vs 美罗培南91.4%(180/197)。
  • 治愈访视复合治愈率:普拉佐米星81.7%(156/191)vs 美罗培南70.1%(138/197)。
  • 碳青霉烯耐药肠杆菌科感染中,普拉佐米星全因死亡或显著疾病相关并发症率为23.5%(4/17),黏菌素为50%(10/20)。
  • 最常见不良反应包括肾功能下降、腹泻、高血压、头痛、恶心、呕吐和低血压。

关键数值与推荐

  • 推荐剂量为15 mg/kg静脉注射,每24小时一次,疗程4-7天。
  • 中度或重度肾功能损害患者需减量并开展治疗药物监测。
  • 严重肾功能损害(包括接受肾脏替代治疗者)不推荐使用普拉佐米星。

临床怎么用

  • 用于替代治疗选择有限或无替代方案的成人cUTI,尤其多重耐药革兰阴性杆菌所致感染。
  • 用药前评估肾功能,中重度肾损者调整剂量并进行TDM。
  • 关注肾功能下降、腹泻、高血压、头痛、恶心、呕吐、低血压等不良反应。
  • 警惕神经肌肉阻滞、耳毒性和孕妇胎儿 harm,与其他氨基糖苷类相同。

局限性

  • 疗效与安全性数据有限,适应证严格限定于替代治疗选择有限的患者。
  • 碳青霉烯耐药肠杆菌科感染证据来自小型III期临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plazomicin is a novel aminoglycoside antibiotic that binds to the bacterial 30S ribosomal subunit, thus inhibiting protein synthesis in a concentration-dependent manner. Plazomicin displays a broad spectrum of activity against aerobic gram-negative bacteria including extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and organisms with aminoglycoside-modifying enzymes. In a large phase III clinical trial, plazomicin was shown to be noninferior to meropenem in the treatment of complicated urinary tract infections (cUTIs) with respect to the coprimary efficacy end points of the microbiologically modified intent-to-treat composite cure rate at day 5 (plazomicin 88% [168/191 subjects] vs meropenem 91.4% [180/197]) and at the test-of-cure visit (plazomicin 81.7% [156/191] vs meropenem 70.1% [138/197]). In a small phase III clinical trial, plazomicin was shown to be effective in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. It was associated with a lower all-cause mortality or significant disease-related complication rate (23.5% [4/17]) compared with colistin (50% [10/20]). The most common adverse reactions associated with plazomicin are decreased renal function, diarrhea, hypertension, headache, nausea, vomiting, and hypotension. As with other aminoglycosides, plazomicin may cause neuromuscular blockade, ototoxicity, and fetal harm in pregnant women. Due to limited efficacy and safety data, plazomicin is indicated for the treatment of cUTIs in adults with limited or no alternative treatment options, using a dosage regimen of 15 mg/kg intravenously every 24 hours for 4-7 days. Dosage reductions and therapeutic drug monitoring are warranted in patients with moderate or severe renal impairment. Plazomicin is not recommended in patients with severe renal impairment including those receiving renal replacement therapy. With the approval of plazomicin, clinicians now have an additional option for the treatment of adults with cUTIs, particularly those caused by multidrug-resistant gram-negative rods.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Shaeer KM, Zmarlicka MT, Chahine EB, et al. Plazomicin: A Next-Generation Aminoglycoside. Pharmacotherapy. 2019. PMID: 30511766. doi:10.1002/phar.2203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。